Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

Stephen H. Culp, Nizar M. Tannir, E. Jason Abel, Vitaly Margulis, Pheroze Tamboli, Surena F. Matin, Christopher G. Wood

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

BACKGROUND: The benefits of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) should outweigh surgical morbidity. Even when the generally agreed upon selection criteria for CN are met, some patients do poorly after surgery. The objective of this study was to identify preoperative factors that were prognostic of outcome in patients who were being considered for CN. METHODS: The authors conducted a retrospective study to investigate the overall survival (OS) of patients who underwent CN using the OS of patients with mRCC who did not undergo CN as a referent group. Patients who underwent CN were divided into 2 groups based on when their OS diverged from that of nonsurgical patients. Chi-square analysis was used to identify variables that differed between the 2 surgical groups. Multivariate Cox proportional hazards regression was used to analyze those variables for the entire CN cohort. Risk factors were defined as preoperative variables that remained significant on multivariate analysis. The median OS and the overall risk of death were calculated based on the number of risk factors. RESULTS: From 1991 to 2007, 566 patients who were eligible for or received systemic therapy underwent CN, and 110 patients received medical therapy alone. On multivariate analysis, independent preoperative predictors of inferior OS in surgical patients included a lactate dehydrogenase level greater than the upper limit of normal, an albumin level less than the lower limit of normal, symptoms at presentation caused by a metastatic site, liver metastasis, retroperitoneal adenopathy, supradiaphragmatic adenopathy, and clinical tumor classification ≥T3. Inferior OS and an increased risk of death were correlated positively with the number of risk factors. Surgical patients who had ≥4 risk factors did not appear to benefit from CN. CONCLUSIONS: The authors of this report identified 7 preoperative variables that permitted them to identify patients who were unlikely to benefit from CN.

Original languageEnglish (US)
Pages (from-to)3378-3388
Number of pages11
JournalCancer
Volume116
Issue number14
DOIs
StatePublished - Jul 15 2010

Fingerprint

Nephrectomy
Renal Cell Carcinoma
Survival
Multivariate Analysis
L-Lactate Dehydrogenase
Patient Selection
Albumins
Retrospective Studies
Neoplasm Metastasis
Morbidity
Liver

Keywords

  • Cytoreductive nephrectomy
  • Metastasis
  • Renal cell carcinoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Culp, S. H., Tannir, N. M., Abel, E. J., Margulis, V., Tamboli, P., Matin, S. F., & Wood, C. G. (2010). Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer, 116(14), 3378-3388. https://doi.org/10.1002/cncr.25046

Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? / Culp, Stephen H.; Tannir, Nizar M.; Abel, E. Jason; Margulis, Vitaly; Tamboli, Pheroze; Matin, Surena F.; Wood, Christopher G.

In: Cancer, Vol. 116, No. 14, 15.07.2010, p. 3378-3388.

Research output: Contribution to journalArticle

Culp, SH, Tannir, NM, Abel, EJ, Margulis, V, Tamboli, P, Matin, SF & Wood, CG 2010, 'Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?', Cancer, vol. 116, no. 14, pp. 3378-3388. https://doi.org/10.1002/cncr.25046
Culp, Stephen H. ; Tannir, Nizar M. ; Abel, E. Jason ; Margulis, Vitaly ; Tamboli, Pheroze ; Matin, Surena F. ; Wood, Christopher G. / Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?. In: Cancer. 2010 ; Vol. 116, No. 14. pp. 3378-3388.
@article{e85835e387564e0384f64a7b518a23d4,
title = "Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?",
abstract = "BACKGROUND: The benefits of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) should outweigh surgical morbidity. Even when the generally agreed upon selection criteria for CN are met, some patients do poorly after surgery. The objective of this study was to identify preoperative factors that were prognostic of outcome in patients who were being considered for CN. METHODS: The authors conducted a retrospective study to investigate the overall survival (OS) of patients who underwent CN using the OS of patients with mRCC who did not undergo CN as a referent group. Patients who underwent CN were divided into 2 groups based on when their OS diverged from that of nonsurgical patients. Chi-square analysis was used to identify variables that differed between the 2 surgical groups. Multivariate Cox proportional hazards regression was used to analyze those variables for the entire CN cohort. Risk factors were defined as preoperative variables that remained significant on multivariate analysis. The median OS and the overall risk of death were calculated based on the number of risk factors. RESULTS: From 1991 to 2007, 566 patients who were eligible for or received systemic therapy underwent CN, and 110 patients received medical therapy alone. On multivariate analysis, independent preoperative predictors of inferior OS in surgical patients included a lactate dehydrogenase level greater than the upper limit of normal, an albumin level less than the lower limit of normal, symptoms at presentation caused by a metastatic site, liver metastasis, retroperitoneal adenopathy, supradiaphragmatic adenopathy, and clinical tumor classification ≥T3. Inferior OS and an increased risk of death were correlated positively with the number of risk factors. Surgical patients who had ≥4 risk factors did not appear to benefit from CN. CONCLUSIONS: The authors of this report identified 7 preoperative variables that permitted them to identify patients who were unlikely to benefit from CN.",
keywords = "Cytoreductive nephrectomy, Metastasis, Renal cell carcinoma, Survival",
author = "Culp, {Stephen H.} and Tannir, {Nizar M.} and Abel, {E. Jason} and Vitaly Margulis and Pheroze Tamboli and Matin, {Surena F.} and Wood, {Christopher G.}",
year = "2010",
month = "7",
day = "15",
doi = "10.1002/cncr.25046",
language = "English (US)",
volume = "116",
pages = "3378--3388",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "14",

}

TY - JOUR

T1 - Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

AU - Culp, Stephen H.

AU - Tannir, Nizar M.

AU - Abel, E. Jason

AU - Margulis, Vitaly

AU - Tamboli, Pheroze

AU - Matin, Surena F.

AU - Wood, Christopher G.

PY - 2010/7/15

Y1 - 2010/7/15

N2 - BACKGROUND: The benefits of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) should outweigh surgical morbidity. Even when the generally agreed upon selection criteria for CN are met, some patients do poorly after surgery. The objective of this study was to identify preoperative factors that were prognostic of outcome in patients who were being considered for CN. METHODS: The authors conducted a retrospective study to investigate the overall survival (OS) of patients who underwent CN using the OS of patients with mRCC who did not undergo CN as a referent group. Patients who underwent CN were divided into 2 groups based on when their OS diverged from that of nonsurgical patients. Chi-square analysis was used to identify variables that differed between the 2 surgical groups. Multivariate Cox proportional hazards regression was used to analyze those variables for the entire CN cohort. Risk factors were defined as preoperative variables that remained significant on multivariate analysis. The median OS and the overall risk of death were calculated based on the number of risk factors. RESULTS: From 1991 to 2007, 566 patients who were eligible for or received systemic therapy underwent CN, and 110 patients received medical therapy alone. On multivariate analysis, independent preoperative predictors of inferior OS in surgical patients included a lactate dehydrogenase level greater than the upper limit of normal, an albumin level less than the lower limit of normal, symptoms at presentation caused by a metastatic site, liver metastasis, retroperitoneal adenopathy, supradiaphragmatic adenopathy, and clinical tumor classification ≥T3. Inferior OS and an increased risk of death were correlated positively with the number of risk factors. Surgical patients who had ≥4 risk factors did not appear to benefit from CN. CONCLUSIONS: The authors of this report identified 7 preoperative variables that permitted them to identify patients who were unlikely to benefit from CN.

AB - BACKGROUND: The benefits of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) should outweigh surgical morbidity. Even when the generally agreed upon selection criteria for CN are met, some patients do poorly after surgery. The objective of this study was to identify preoperative factors that were prognostic of outcome in patients who were being considered for CN. METHODS: The authors conducted a retrospective study to investigate the overall survival (OS) of patients who underwent CN using the OS of patients with mRCC who did not undergo CN as a referent group. Patients who underwent CN were divided into 2 groups based on when their OS diverged from that of nonsurgical patients. Chi-square analysis was used to identify variables that differed between the 2 surgical groups. Multivariate Cox proportional hazards regression was used to analyze those variables for the entire CN cohort. Risk factors were defined as preoperative variables that remained significant on multivariate analysis. The median OS and the overall risk of death were calculated based on the number of risk factors. RESULTS: From 1991 to 2007, 566 patients who were eligible for or received systemic therapy underwent CN, and 110 patients received medical therapy alone. On multivariate analysis, independent preoperative predictors of inferior OS in surgical patients included a lactate dehydrogenase level greater than the upper limit of normal, an albumin level less than the lower limit of normal, symptoms at presentation caused by a metastatic site, liver metastasis, retroperitoneal adenopathy, supradiaphragmatic adenopathy, and clinical tumor classification ≥T3. Inferior OS and an increased risk of death were correlated positively with the number of risk factors. Surgical patients who had ≥4 risk factors did not appear to benefit from CN. CONCLUSIONS: The authors of this report identified 7 preoperative variables that permitted them to identify patients who were unlikely to benefit from CN.

KW - Cytoreductive nephrectomy

KW - Metastasis

KW - Renal cell carcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77954937811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954937811&partnerID=8YFLogxK

U2 - 10.1002/cncr.25046

DO - 10.1002/cncr.25046

M3 - Article

C2 - 20564061

AN - SCOPUS:77954937811

VL - 116

SP - 3378

EP - 3388

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 14

ER -